Pentosan Polysulfate Treatment's Effectiveness

Not Applicable

Completed

• Conditions: Chronic Interstitial Cystitis
• Interventions: Other: Pentosan Polysulphate

• Registration Number: NCT05744908
• Lead Sponsor: Hisar Intercontinental Hospital

Brief Summary

To examine the relationship between symptoms and quality of life before and after oral pentosan polysulfate (PPS) treatment in cases diagnosed with interstitial cystitis/painful bladder syndrome (IC/BPS).

Detailed Description

Demographic characteristics, medical history, clinical conditions, and laboratory and cystoscopic data of patients who applied to our clinic between January 2018 and December 2021 and were diagnosed with IC/BPS were retrospectively analyzed. Adult male and female patients with IC/BPS who received 300 mg/day PPS at least six months ago with complaints of pain, urge, frequency, and nocturia not associated with urinary tract infection were included in the study. In addition, pre- and post-treatment symptoms, ICSI scores, quality of life (scored between 1-4), and satisfaction were compared.

Study Timeline

• Study Start: 2018-01-01
• Primary Completion: 2021-12-31
• Study Completion: 2023-01-10
• Study First Submitted: 2023-01-10
• Status Verified: 2023-02
• Study First Submitted QC: 2023-02-15
• Study First Posted: 2023-02-27
• Last Update Submitted: 2025-05-19
• Last Update Posted: 2025-05-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

• Chronic interstitial cystitis
• Bladder Pain Syndrome

Exclusion Criteria

• Acute cystitis
• Bladder cancer
• Chronic prostatitis
• Bladder stone
• Stress incontinence

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
With Hunner's ulcer	Pentosan Polysulphate	Pentosan Polysulfate 100 mg
Without Hunner's ulcer	Pentosan Polysulphate	Pentosan Polysulfate 100 mg

Primary Outcome Measures

Name	Time	Method
improvement of lower urinary tract symptoms	Three months	1 if symptoms improved, 0 if not
bladder wall thickness	Three months	0.3 over 3 mm 1 under 3 mm,

Trial Locations

Locations (2)

Hisar Intercontinental Hospital; 🇹🇷 Istanbul, Turkey

Basri Cakiroglu; 🇹🇷 Istanbul, Turkey